^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR L861Q

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    6d
    KANNON-5: Andamertinib as First-line Treatment for NSCLC With EGFR PACC or EGFR L861Q Mutation (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Avistone Biotechnology Co., Ltd.
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q
    |
    andamertinib (PLB1004)
    10d
    AURA17: Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific (clinicaltrials.gov)
    P2, N=171, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib)
    10d
    TROPION Lung15: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=744, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting
    Enrollment open
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • simmitinib (SYHA1817)
    11d
    Individualized management strategies for advanced non-small cell lung cancer with EGFR exon 19 deletion and L861Q compound mutations based on circulating tumor DNA monitoring: A case report. (PubMed, Oncol Lett)
    The present case emphasized the importance of individualized management and the key role of ctDNA in real-time treatment monitoring, offering a potentially novel approach for precise disease evaluation in the future. Further research and the development of novel therapies are warranted to potentially improve outcomes in patients with advanced EGFR-mutated NSCLC.
    Journal • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q
    |
    Ameile (aumolertinib)
    28d
    NCI-2021-04325: Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    30d
    WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov)
    P1, N=55, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Dec 2030
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR amplification • EGFR L861Q • IDH wild-type
    |
    WSD0922
    1m
    OSU-20298: Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • tegavivint (BC2059)
    2ms
    Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. (PubMed, J Clin Oncol)
    In participants with atypical EGFR-mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    2ms
    Application of pleural effusion cell blocks for immunohistochemistry and EGFR gene mutation testing for advanced lung cancer. (PubMed, Exp Ther Med)
    Furthermore, patients with EGFR-mutant lung adenocarcinoma undergoing treatment with EGFR tyrosine kinase inhibitors exhibited a significantly extended survival rate compared with those with wild-type EGFR receiving chemotherapy. In conclusion, the present study demonstrated that immunohistochemistry with pleural effusion cell blocks can aid in clarifying the histological subtype of lung cancer, and enable EGFR mutation detection, which can effectively guide molecular targeted therapy.
    Journal • Pleural effusion
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR wild-type • EGFR L861Q • EGFR G719X • EGFR S768I
    2ms
    Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy. (PubMed, Oncol Ther)
    First-line osimertinib may provide real-world clinical benefits for patients with advanced NSCLC with atypical EGFR mutations, with results suggesting greater benefit in those harboring compound EGFR mutations.
    Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib)
    3ms
    An exploratory study on tuvonralimab/iparomlimab combined with chemotherapy for the treatment of advanced non-small cell lung cancer patients with EGFR uncommon mutations (ChiCTR2500111278)
    P=N/A, N=20, Not yet recruiting, Cancer Hospital, Chinese academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences
    New trial
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3ms
    A Single-Arm Clinical Study of Ivonescimab Combined with Targeted Therapy and Intrathecal Therapy for Leptomeningeal Metastasis in EGFR/ALK-Positive Non-Small Cell Lung Cancer​ (ChiCTR2500109516)
    P1/2, N=30, Not yet recruiting, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital, The Affiliated Hospital of Nan
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • KIF5B (Kinesin Family Member 5B) • TPM3 (Tropomyosin 3) • HIP1 (Huntingtin Interacting Protein 1)
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR positive
    |
    Yidafan (ivonescimab)